Core Viewpoint - Inspire Medical Systems, Inc. is set to release its financial results for the fourth quarter and fiscal year 2024 on February 10, 2025, followed by a conference call to discuss these results and recent business developments [1]. Financial Results Announcement - The financial results will be announced after the close of trading on February 10, 2025 [1]. - A conference call will take place at 5:00 p.m. Eastern Time to discuss the results [1]. Conference Call Details - A webcast of the conference call will be available on the Investor Relations page of Inspire's website [2]. - For those wishing to ask questions, registration is required, and an email will be sent with dial-in details and a unique access code [3]. - It is recommended to register at least 10 minutes before the call starts to ensure connection [3]. Replay Information - A replay of the conference call will be available on the Company's Investor Relations website approximately two hours after the event and will be archived for two weeks [4]. Company Overview - Inspire Medical Systems focuses on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea [5]. - The company's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [5].

Core Insights - Inspire Medical Systems, Inc. is a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea [3] - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 11:15 a.m. Eastern Time [2] Company Overview - Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [3] - The company focuses on the development and commercialization of innovative solutions for patients suffering from this condition [3] Investor Relations - The presentation will be accessible via a live webcast, and replays will be available for two weeks following the event [4]

VANCOUVER, British Columbia and AUSTIN, Texas, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Inspire Semiconductor Holdings Inc. (TSXV: INSP) (“InspireSemi” or the “Company”), a chip design company that provides revolutionary high-performance, energy-efficient accelerated computing solutions for High Performance Computing (HPC), AI, graph analytics, and other compute-intensive workloads, announces that following the approval of a majority of the minority of the Company’s shareholders at an annual general and special me ...

Group 1 - BofA Securities has upgraded Inspire Medical Systems from Neutral to Buy, indicating the company is now categorized under profitable growth [1][3][6] - Inspire Medical is expected to provide its 2025 revenue guidance in early January, aligning with its fourth-quarter results, and is comfortable with the consensus of $950 million in revenue for 2025 [1][3] - For 2024, Inspire Medical anticipates sales between $793 million and $798 million, slightly above prior guidance and in line with consensus estimates [2] Group 2 - The company's growth outlook for 2025 includes plans to hire more staff, open new centers, increase direct-to-consumer advertising, expand treatment indications, and enhance capacity [3] - The Inspire V system, approved by the FDA, is expected to simplify procedures and increase accessibility for various types of surgeons, with a soft launch planned for late 2024 and a full launch in 2025 [4][5] - The analyst notes that Inspire Medical is positioned as an attractive smid cap growth stock with potential for double-digit margins, which could lead to increased strategic interest [6]

MINNEAPOLIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Inspire is scheduled to present at 7:30 a.m. Eastern Time. The presentation will be accessible via a live webcast ...

Core Viewpoint - Inspire Medical Systems, Inc. has announced an accelerated share repurchase transaction of $75 million as part of a $150 million share repurchase program, reflecting confidence in its long-term growth potential and commitment to enhancing shareholder value [1][2]. Group 1: Share Repurchase Program - The company has entered into an accelerated share repurchase (ASR) transaction with Goldman Sachs to repurchase $75 million of its common stock [1]. - This ASR is part of a previously announced $150 million share repurchase program authorized by the Board of Directors [1]. - The ASR transaction is expected to conclude in the first quarter of 2025 [2]. Group 2: Management's Perspective - The Chairman and CEO of Inspire expressed confidence in the company's long-term growth potential, supported by strong revenue and earnings growth, and future cash generation expectations [2]. - The company aims to balance future growth investments with shareholder value enhancement through a disciplined capital allocation strategy, which may include opportunistic share repurchases [2]. Group 3: Share Repurchase Considerations - In deciding the capital allocation for share repurchases, the company evaluates its historical and expected business performance, cash and liquidity position, and market conditions [3]. - The timing, manner, price, and amount of repurchases are at the company's discretion, and the program may be modified or discontinued at any time [3]. - The share repurchase program is set to expire on August 5, 2026, unless terminated or extended by the Board [3]. Group 4: Company Overview - Inspire Medical Systems focuses on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea [4]. - The company's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [4].

Inspire Medical Systems, Inc. (INSP) delivered an earnings per share (EPS) of 60 cents in third-quarter 2024 against the year-ago period’s loss of 29 cents per share. The metric surpassed the Zacks Consensus Estimate by a huge 900%.INSP’s Revenues in DetailInspire Medical registered revenues of $203.2 million in the third quarter, up 32.5% year over year. The figure beat the Zacks Consensus Estimate by 2.8%.Per management, the top-line growth was driven by increased market penetration in existing centers, e ...

For the quarter ended September 2024, Inspire Medical Systems (INSP) reported revenue of $203.19 million, up 32.5% over the same period last year. EPS came in at $0.60, compared to -$0.29 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $197.65 million, representing a surprise of +2.81%. The company delivered an EPS surprise of +900.00%, with the consensus EPS estimate being $0.06.While investors closely watch year-over-year changes in headline numbers -- revenue and ...

Inspire Medical Systems (INSP) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 900%. A quarter ago, it was expected that this maker of devices for treating obstructive sleep apnea would post a loss of $0.14 per share when it actually produced earnings of $0.32, delivering a surprise of 32 ...

Core Insights - Inspire Medical Systems reported a strong financial performance for Q3 2024, with a revenue of $203.2 million, marking a 33% increase year-over-year [2][3] - The company achieved a gross margin of 84.1% and generated an operating income of $14.3 million, a significant turnaround from an operating loss of $13.5 million in the prior year [4][5] - Inspire is increasing its full-year revenue guidance to between $793 million and $798 million, reflecting a growth of 27% to 28% over 2023 [6][7] Recent Business Highlights - Revenue for Q3 2024 was $203.2 million, a 33% increase from $153.3 million in Q3 2023 [3] - U.S. revenue for the quarter was $195.8 million, also a 33% increase compared to the prior year [3] - The company activated 66 new U.S. centers in Q3 2024, bringing the total to 1,371 centers [2] - Inspire created 13 new U.S. sales territories, increasing the total to 323 [2] - The Inspire V neurostimulation system received FDA approval [2] Financial Performance - Gross margin remained stable at 84.1% for both Q3 2024 and Q3 2023 [3] - Operating expenses increased to $156.5 million, a 10% rise from $142.4 million in the prior year [4] - Net income for Q3 2024 was $18.5 million, compared to a net loss of $8.5 million in Q3 2023 [5] - Diluted earnings per share for Q3 2024 were $0.60, up from a diluted net loss of $0.29 per share in the prior year [5] Full Year Guidance - The company raised its full-year 2024 revenue guidance to $793 million to $798 million, up from the previous guidance of $788 million to $798 million [6] - Full-year earnings per share guidance was increased to $1.20 to $1.40, compared to the prior range of $0.60 to $0.80 [7] - Inspire maintains its guidance for opening 52 to 56 new U.S. medical centers per quarter [7]